Great West Life Assurance Co. Can Sells 10,753 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Other institutional investors and hedge funds also recently modified their holdings of the company. Valeo Financial Advisors LLC raised its position in shares of NeoGenomics by 150.0% in the third quarter. Valeo Financial Advisors LLC now owns 1,000 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 600 shares during the period. Fiduciary Planning LLC acquired a new position in shares of NeoGenomics in the third quarter valued at about $41,000. FinTrust Capital Advisors LLC grew its stake in shares of NeoGenomics by 27.0% in the third quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 270 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of NeoGenomics by 48.0% in the third quarter. Flagship Harbor Advisors LLC now owns 1,310 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 425 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of NeoGenomics in the third quarter valued at about $55,000. 86.09% of the stock is currently owned by institutional investors.
NeoGenomics stock opened at $53.84 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.22 and a current ratio of 6.54. NeoGenomics, Inc. has a 52-week low of $20.47 and a 52-week high of $57.07. The firm has a 50 day moving average price of $49.10 and a two-hundred day moving average price of $40.10. The firm has a market cap of $5.98 billion, a price-to-earnings ratio of -1,794.07 and a beta of 0.78.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $125.40 million during the quarter, compared to the consensus estimate of $126.23 million. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.07 EPS. As a group, equities research analysts predict that NeoGenomics, Inc. will post -0.01 EPS for the current fiscal year.
NEO has been the topic of a number of analyst reports. Craig Hallum increased their price objective on shares of NeoGenomics from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. SVB Leerink increased their price objective on shares of NeoGenomics from $47.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, November 20th. Raymond James increased their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Benchmark increased their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Finally, Needham & Company LLC increased their target price on shares of NeoGenomics from $39.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. NeoGenomics currently has a consensus rating of “Buy” and a consensus price target of $40.96.
In other NeoGenomics news, CEO Oort Douglas M. Van sold 340,000 shares of NeoGenomics stock in a transaction on Monday, November 16th. The shares were sold at an average price of $42.01, for a total transaction of $14,283,400.00. Following the transaction, the chief executive officer now directly owns 2,384,038 shares of the company’s stock, valued at approximately $100,153,436.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Bonello sold 8,000 shares of NeoGenomics stock in a transaction on Wednesday, December 2nd. The stock was sold at an average price of $46.80, for a total transaction of $374,400.00. Following the transaction, the insider now directly owns 20,060 shares in the company, valued at $938,808. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 754,561 shares of company stock valued at $33,557,193. Insiders own 6.50% of the company’s stock.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Read More: Basic Economics creates winners and losers
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source